Keywords: statins, account, first-line, dyslipidemia, treatment, despite, dominant
Statins account for 81% of first-line dyslipidemia treatment
Article | 30 January 2006
Despite the dominant market position of statins in the treatment of dyslipidemia, or cholesterol-lowering, only 81% of patients receive such medicines ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Italy's pharma market slump set to continue, warns GlobalData
- Is failure to adopt business process management putting the pharma industry at risk?
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
